Antibodies to platelet glycoprotein V in polytransfused patients with haematological disease.
Polytransfused patients often develop platelet-reactive antibodies (PRAb). These give positive reactions in the platelet immunofluorescence test (PIFT) and may be either lymphocytotoxic (LCTAb) or platelet-specific antibodies (PSAb). The latter may be detected in the PIFT using chloroquine-treated platelets (Chl-PIFT) or by immunoblotting. Serial samples from 106 multiply transfused patients with bone marrow failure were screened by PIFT using a microplate method and flow-cytometric analysis. PSAb activity was confirmed by Chl-PIFT. In 45 (42%) of the patients studied PSAb were detected; 37 (35%) formed LCTAb and 19 (51%) had co-existent PSAb. Sera from 25 of 27 patients with a positive Chl-PIFT, retested by immunoblotting, recognised determinants of Mr 82-160 kD on whole platelets. A large group became sensitised to a component of Mr 105-115 kD reduced (99 kD non-reduced) with similar electrophoretic mobility to GPIIIa using a monoclonal anti-GPIIIa and two human polyclonal anti-HPA-1a sera; some also produced anti-GPIIb. The largest group recognised a determinant of Mr 80-83 kD, probably glycoprotein V (GPV). Three sera were immunoblotted against thrombin-treated platelets and the results confirmed GPV specificity.
Meenaghan
M
M
South West Regional Transfusion Centre, Bristol, UK.
Judson
P A
PA
Yousaf
K
K
Lewis
L
L
Pamphilon
D H
DH
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D015151:Immunoblotting; D007223:Infant; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D011897:Random Allocation; D065227:Transfusion Reaction
D001323:Autoantibodies; D010980:Platelet Membrane Glycoproteins